AstraZeneca CFO on Profit Guidance, Expansion, Vaccine Demand

The video discusses AstraZeneca's increased revenue and EPS guidance due to strong demand across various units, including oncology, cardiovascular, and respiratory. It highlights the decline in vaccine revenue and the underappreciated potential of the Alexion rare disease portfolio. The company continues to invest in R&D and maintains a strong presence in China and the UK, emphasizing the need for attractive industry conditions in the UK.

How much did AstraZeneca invest in R&D this quarter?

What challenges does AstraZeneca face in the Chinese market?

What does AstraZeneca suggest the UK government should focus on to support growth?